The patent describes LGD-4665 and other small-molecule thrombopoietin mimetic compounds discovered at Ligand, formulations involving these compounds, as well as methods of making and using the compounds and formulations. LGD-4665 has the potential to become a competitive molecule for the treatment of different forms of thrombocytopenia.
John Higgins, president and CEO of Ligand, said: “Receipt of this patent reflects our continued focus on innovation while strengthening our intellectual property portfolio, and covers a platform molecule that we believe has significant market potential.”